Connect with us

Top Stories

NBA saw its first 7-team trade this summer. Here’s how — and why — it unfolded

Published

on


How does a seven-team trade come together? Much like that old saying about how to eat an elephant: one bite at a time.

Having been on the inside as many transactions have developed (I was vice president of basketball operations for the Memphis Grizzlies from 2012-19), I can tell you that an NBA blockbuster of this size is usually just an amalgamation of several smaller deals.

Let’s start with the basics that help explain why: Sometimes it’s a lot more advantageous for a team to construct a multi-team trade rather than doing the same deals sequentially. This is because the trade exception available in what the collective bargaining agreement terms a “simultaneous trade” is larger than the one available if deals are done sequentially, even if the second trade happens mere minutes after the first.

To give you an example, the Grizzlies had a deal set up at the 2016 trade deadline to send Courtney Lee to the Charlotte Hornets for Brian Roberts, P.J. Hairston and two second-round picks. However, the two incoming players made less than what Lee made, which meant we could legally stuff a lot more money into the trade, and we had enough room under the luxury tax to do so. So we were incentivized to try to get more money into the deal if somebody would pay us to do it.

If we did a straight Lee-for-Roberts trade, the trade exception we created would have only been for the difference between their salaries ($1.6 million at the time). But if we traded Lee for other salaries at the same time, we could take back up to 150 percent of what he made. (That was the rule at the time; it has since become more liberal regarding simultaneous trade exceptions, and the 2023 CBA allows the nontaxpayer midlevel exception to be converted to a trade exception.)

So … we found more salary. Enter the Miami Heat, who were over the luxury tax, facing the CBA’s repeater penalty and needed to reduce their payroll. We agreed to send Roberts to them and take back Chris Andersen, who made nearly twice as much, in return for a second-round pick and another protected second-rounder. We couldn’t have traded Roberts for Andersen any other way.

Voila, a three-team trade. Critically, the deal met the league’s “touching” requirements for three-team deals because each part of the Memphis-Charlotte-Miami triangle had consideration going their way.

That’s how three-team deals start, and from there, they can often mushroom into something larger. Take the seven-team deal featuring Kevin Durant that was completed Sunday, for example. It stemmed almost entirely from five different trades agreed to the week of the draft, with only the final addition of the Atlanta Hawks having any connection to free agency. Theoretically, the other four deals could have happened sequentially after the first; it was just a lot cleaner for everyone to do it as a multi-team trade.

But that’s not the only way a huge multi-team deal can happen. A year earlier, Golden State’s Klay Thompson was signed and traded to the Dallas Mavericks in a deal that ended up involving six teams, as each step in the chain made another deal to take advantage of the trade exception from the first one. At the trade deadline in 2024, a four-team deal between Golden State, Portland, Detroit and Atlanta nearly blew up over a failed physical by Gary Payton II.

July 6 (when teams can begin officially signing free agents to contracts) and the trade deadline are usually the only times we see deals mushroom beyond three teams … and for opposite reasons. On July 6, it’s because teams have all the time in the world between the draft and the end of the free-agency moratorium to improve upon deals that were already negotiated, potentially combining completely separate transactions in ways that maximize trade exceptions. At the trade deadline, however, it’s because there’s no time left; you couldn’t do a sequential trade even if you wanted, because it will never get approved by the league in time for the next one to beat the deadline buzzer.

This offseason, Houston negotiated a straightforward deal with Phoenix to send the 10th pick, five second-round picks, Dillon Brooks and Jalen Green to Phoenix for Durant. However, the Rockets had two weeks — and the entire draft — before they needed to officially execute the deal. They realized they could stuff more money into the trade if they added another contract when free agency started and recruited Atlanta to join a sign-and-trade involving big man Clint Capela. The teams completed the “touching” requirement, as well as the requirement that each team both give and receive something in a trade, by having Atlanta send two-way player Daeqwon Plowden to Phoenix and Houston send two-way player David Roddy to Atlanta. (Both players were immediately waived after the trade was official. Fun times!)

Conditions for a seven-team trade ensued when the Suns began spraying those second-round picks from Houston all over the league on draft night, using four of them on subsequent trades. The 59th pick in the draft that originated with Houston went to Phoenix, then Golden State, then Memphis. (The Grizzlies weren’t part of the seven-team deal and completed their portion with the Warriors afterward.)

Meanwhile, the Suns’ own second-round pick, at No. 52, was also sent to Golden State to give the Suns the 41st pick. So now the Warriors were team No. 4 for our trade, meeting “touching” requirements with one pick from Houston and one pick from Phoenix. The rights to pick No. 41 (Koby Brea), pick No. 52 (Alex Toohey) and pick No. 59 (Jahmai Mashack) were in the deal.

But wait, there’s more! The Suns put two other future second-round picks from Houston in play to acquire the 36th pick from the Brooklyn Nets. And then they traded that pick and another to the Minnesota Timberwolves to move up to No. 31 and draft Rasheer Fleming. And then Minnesota traded that 36th pick to the Los Angeles Lakers for cash and the 45th pick (Rocco Zikarsky).

So now, we had Brooklyn, Minnesota and the Lakers involved, and they all had triangles that allowed a multi-team trade. The Lakers were sending cash and the 45th pick to the Wolves but getting pick No. 36 from Brooklyn. (L.A. had previously obtained the pick in a straight two-team draft-night transaction with the Bulls.) The Wolves were getting the 45th pick from L.A. but sending pick No. 31 to Phoenix and also receiving two future seconds from the Suns. Finally, the Nets were sending out the 35th pick to the Lakers but receiving two future seconds that originated in Houston.

The real mystery here is why Memphis didn’t join the fray and make it an eight-team trade. The Grizzlies sent out their own pick (56th) to Golden State and received the 59th pick that originated in Houston, as well as consideration from the Warriors. Based on my admittedly brief and not exhaustive investigation into this crucial topic, it seems at least one of the two teams might have wanted to keep this trade on the side in case they needed it as a starting point for their own multi-team trade.

We saw a similar dynamic at work a year earlier in the 2024 Thompson deal, except it was perhaps even more complicated and fun because it wasn’t the result of a playing 52-pickup from draft night. Those trades were glued together because of valuable trade exceptions, similar to my Memphis example above, and show why we’ll probably see this more in the future.

The Warriors’ deal with Buddy Hield was converted to a sign-and-trade that benefited the Philadelphia 76ers by generating a trade exception for them. At the same time, the more permissive rules for trade exceptions meant the Warriors could put Hield into the Thompson trade and still stuff in another contract, so they piled in a sign-and-trade with Minnesota for Kyle Anderson.

Right away, we had a four-team banger, but then we had Dallas’ side of the Thompson deal. The Hornets sent two second-round picks to Dallas for Josh Green, which enabled Dallas to do the Thompson deal as a three-team sign-and-trade if one of those picks ended up in Golden State. Via creative rerouting of other second-round picks in the deal, it was easy to loop in Minnesota and Philly.

The final leg was Denver, which had its own side deal with Charlotte to send two seconds to the Hornets to salary-dump Reggie Jackson. But one of those picks was destined for Dallas and then points beyond, so Denver was in the deal, too; it just required a third team to send a small trinket (in this case, cash) back to the Nuggets.

So that, my friends, is how you end up with a six- or seven-team trade. Most executives don’t wake up in the morning and say, “Hey, I have this great idea for a seven-team deal!” (I can think of two or three exceptions whom I will not name, but they know who they are.)

As I alluded to above, I expect deals like this to happen much more often. And unlike this most recent seven-team deal, I think they’re more likely to follow the example of the 2024 Thompson trade and involve a lot of active NBA players too.

We’ve had our multi-team fun for 2025, but get your popcorn ready for next summer.

(Illustration: Kelsea Petersen / The Athletic; Alex Slitz, Tim Warner, Barry Gossage / Getty Images)



Source link

Top Stories

Novartis receives approval for first malaria medicine for newborn babies and young infants

Published

on


  • Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants
  • Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)
  • Novartis plans to introduce infant-friendly Coartem Baby on largely not-for-profit basis to increase access in areas where malaria is endemic

Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Eight African countries also participated in the assessment and are now expected to issue rapid approvals under the Swiss agency’s Marketing Authorization for Global Health Products procedure.1 Novartis plans to introduce the infant-friendly treatment on a largely not-for-profit basis to increase access in areas where malaria is endemic.

“For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most,” said Vas Narasimhan, CEO of Novartis. “Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve.”

Until now, there has been no approved malaria treatment for infants weighing less than 4.5 kilograms, leaving a treatment gap. They have instead been treated with formulations intended for use in older children, which may increase the risk of overdose and toxicity. Malaria vaccines are also not approved for the youngest babies.2

Some 30 million babies are born in areas of malaria risk in Africa every year,3 with one large survey across West Africa reporting infections ranging between 3.4% and 18.4% in infants younger than 6 months old.4 However, current data on malaria in young babies is extremely limited as they are rarely included in clinical trials of antimalarial agents.5,6

“The available malaria treatments have only been properly tested in children aged at least 6 months because smaller infants are usually excluded from treatment trials,” said Professor Umberto D’Alessandro, Director of the MRC Unit, The Gambia at the London School of Hygiene and Tropical Medicine. “That matters because neonates and young infants have immature liver function and metabolize some medicines differently, so the dose for older children may not be appropriate for small babies.”

The new dose strength designed for young infants was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica consortium, which is co-funded by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer. 

“Malaria is one of the world’s deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,” said Martin Fitchet, CEO of MMV. “The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.”

About the CALINA study
The Swissmedic approval is based on the Phase II/III CALINA study, which investigated a new ratio and dose of Coartem (artemether-lumefantrine) to account for metabolic differences in babies under 5 kilograms. It is indicated for the treatment of infants and neonates weighing between 2 and less than 5 kilograms with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum. Coartem is known by the brand name Riamet in Switzerland and some other countries.

About malaria
Malaria is a life-threatening disease caused by a parasite and spread to humans by some types of mosquitoes. According to the most recent WHO data, there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa. Children under 5 years old accounted for about three in four malaria deaths in the region.7

About Novartis in malaria innovation
Novartis finds breakthroughs for diseases neglected by science and brings innovative medicines to communities on the margins of healthcare, building on 85 years of innovation in global health. Novartis has built the industry’s largest pipeline of treatments to control or eliminate malaria and neglected tropical diseases, backed by nearly USD 490 million in funding for global health R&D since 2021. This includes four new antimalarial compounds with the potential to combat rising drug resistance, one of which is just completing Phase III trials, and another which is a potential single-dose cure. Since 1999, Novartis has delivered more than 1.1 billion treatment courses of antimalarials, mostly at no profit, including 500 million treatments of a child-friendly formulation for babies weighing at least 5 kilograms.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

About MMV
MMV is a Swiss not-for-profit working to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Born in 1999 to drive health equity, MMV closes critical gaps in research, development and access – to expand the use of existing antimalarials and innovate new compounds. This starts with women and children. As of 2024, MMV-supported products have effectively treated more than 711 million patients.

For more information, visit www.mmv.org Follow MMV on social media: X, LinkedIn, YouTube and Facebook 

References

  1. Eight African countries participated in Swissmedic’s Marketing Authorization for Global Health Products (MAGHP) procedure for Coartem Baby – Burkina Faso, Cote d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda — and are expected to approve the medicine following approval by Swissmedic. These eight countries account for 47% of estimated cases in 2023, according to the WHO’s Global Health Observatory
  2. WHO. Malaria vaccines (RTS,S and R21)
  3. Reddy, Valentina et al. Global estimates of the number of pregnancies at risk of malaria from 2007 to 2020: a demographic study. The Lancet Global Health, Volume 11, Issue 1, e40 – e47
  4. Ceesay SJ et al. Malaria Prevalence among Young Infants in Different Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21. doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.
  5. D’Alessandro U, et al. Malaria in infants aged less than six months – is it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi: 10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.
  6. Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first year of life. Parasitology. 2016;143(2):129-138. doi:10.1017/S0031182015001626
  7. WHO. Malaria.

# # #





Source link

Continue Reading

Top Stories

Dow, S&P 500, Nasdaq Gain Despite Trump Trade Fears; Nvidia Market Cap; Tariffs Deadline Delayed; Dollar Rises; Treasury Yields Fall; Tesla, Wolfspeed, T-Mobile and More Movers

Published

on


Banks are set to mark the unofficial start to earnings season next week, and the reports come with the major indexes all within striking distance of their highest levels on record.

The S&P 500 was up 0.3% on Wednesday. The Nasdaq Composite was up 0.6%. The Dow was up 103 points, or 0.2%.

The CBOE Volatility Index, or VIX, is down to its lowest levels since February at 16.

John Higgins, chief markets economist at Capital Economics, argues the coming earnings reports could shine some initial light on corporate America’s role in shouldering the impact of tariffs already in place—whether that’s foreign firms exporting, U.S. firms importing, or through higher consumer prices.

Though the Bureau of Economic Analysis won’t release its preliminary estimate of corporate profits for the second quarter until late August, Higgins thinks higher tariffs may become apparent in micro data this earnings season.

“Higher tariffs ought to show up in a firm’s cost of goods sold (COGS),” he writes. “So a key metric to watch is gross profit margin, which is gross profit (the difference between sales and COGS) divided by sales.”

He argues analysts don’t seem to expect corporations to shoulder much of the future tariff burden.

“There is some evidence at the firm level of analysts paring back their forward twelve month (FTM) expectations for gross profit margin around the time of Liberation Day,’” Higgins writes. “But for the US stock market as a whole, there hasn’t been a big downgrading. … A glass-half-empty view would be that there is plenty of (pun-pardoning) margin for error.”



Source link

Continue Reading

Top Stories

Trump threatens more countries with tariffs as high as 30%

Published

on




CNN
 — 

President Donald Trump sent letters to the leaders of seven more countries Wednesday, adding to the growing list of US trading partners for whom he has threatened new tariff rates.

Among the latest recipients were the Philippines, Sri Lanka, Moldova, Brunei, Algeria, Libya and Iraq, with rates going as high as 30% on goods they ship to the United States. The new tariffs go into effect August 1, pending negotiations.

Trump said Wednesday afternoon that he planned to announce his tariff level for Brazil within the next day or two. “Brazil as an example, has been not good to us. Not good at all,” he said during a White House multilateral meeting with leaders of African nations. “We’re going to be releasing a Brazil number, I think, later on, this afternoon or tomorrow morning.”

The rates Trump said would be imposed on goods from Sri Lanka, Moldova, Iraq and Libya were lower than those he announced in early April. The rates on goods from the Philippines and Brunei were higher, compared to April levels. Meanwhile, the rate on goods from Algeria was the same (30%) as April levels.

Collectively, the US imported $29 billion worth of goods from those seven nations last year, according to US Commerce Department figures. That accounts for less than 1% of the $3.2 trillion of goods the US imported.

US stocks were mostly unchanged after Trump’s posts. The Dow was up 50 points, or 0.11%. The S&P 500 was up 0.25% and the tech-heavy Nasdaq gained 0.58%.

The US and various trading partners have been negotiating new trade agreements since Trump announced so-called “reciprocal” tariffs back in April. Yet few deals have come to fruition.

During a cabinet meeting on Tuesday, Trump said “a letter means a deal.” But that doesn’t appear to be how some countries are perceiving the missives.

In the letters, Trump wrote that he takes particular issue with the trade deficits the United States runs with other nations, meaning America buys more goods from there compared to how much American businesses export to those countries. Trump also said the tariffs would be set in response to other policies that he deems are impeding American goods from being sold abroad.

Trump has encouraged world leaders to manufacture goods in the United States to avoid tariffs. If they chose to retaliate by slapping higher tariffs on American goods, Trump threatened to tack that onto the rate charged on their country’s goods shipped to the United States.

Trump has now sent 21 letters on tariff rates to heads of state this week, and more could still come. The 25% tariff Trump threatened to impose on Japan and South Korea would be most likely to impact prices of goods Americans buy, since the two nations are America’s fifth- and seventh-top sources of foreign goods.

Wednesday at 12:01 a.m. ET was the initial deadline Trump set three months ago for countries to ink trade deals with the US or instantly face higher tariff rates. However, on Monday he extended that deadline to August 1.

This is a developing story. It will be updated.



Source link

Continue Reading

Trending